Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AN2 Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform. Its disclosures cover common stock registration, operating and financial results, clinical and regulatory updates, risk factors and material events related to its development pipeline.
ANTX filings also include proxy materials for director elections and auditor ratification, 8-K reports on material agreements, equity and warrant financing arrangements, at-the-market sale agreements, equity incentive plan matters, option repricing, officer appointments, governance changes and capital-structure disclosures.
AN2 Therapeutics Chief Development Officer Sanjay Chanda reported new equity awards. On February 20, 2026, he received a grant of stock options for 77,000 shares at an exercise price of $0.00 per share, vesting monthly over four years from January 1, 2026.
He also acquired 38,000 shares of common stock as restricted stock units that vest annually in four installments from January 1, 2026, subject to continued service. Following these awards, he directly holds 77,000 options and 118,823 common shares, which include previously granted RSUs and shares purchased under the 2022 Employee Stock Purchase Plan.
Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Marks Gilbert Lynn reported receiving a grant of stock options covering 20,400 shares. The options are scheduled to vest on February 20, 2027, provided he continues to provide service to the company through that date.
Readnour Robin Shane reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Robin Shane Readnour reported an equity award in the form of stock options for 20,400 shares. The options were granted as a compensation award and will vest on February 20, 2027, provided Readnour continues to provide service to the company through that date.
AN2 Therapeutics, Inc. director Stephanie Wong received a grant of stock options covering 20,400 shares on February 20, 2026. The options were granted at an exercise price of $0.00 per share and will vest on February 20, 2027, provided she continues to serve through that date.
AN2 Therapeutics director Patricia A. Martin received a stock option grant for 20,400 shares of common stock of AN2 Therapeutics, Inc. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
The option shares will vest on February 20, 2027, provided Martin continues to provide service to the company through that date. Following this award, she holds 20,400 option shares directly, aligning her compensation more closely with the company’s future share performance.
AN2 Therapeutics, Inc. director Melvin K. Spigelman reported receiving a grant of stock options covering 20,400 shares of the company’s stock. The award was recorded as an acquisition of derivative securities held directly by him. According to the filing, these option shares will vest on February 20, 2027, provided he continues to provide service to the company through that date.
AN2 Therapeutics director Aziz Kabeer received a grant of 20,400 stock options (right to buy) on February 20, 2026. The options have an exercise price of $0.00 per share and are held directly.
The option shares are scheduled to vest on February 20, 2027, provided Kabeer continues to provide service to the company through that date. After this grant, he holds 20,400 derivative securities related to the company’s stock options.
AN2 Therapeutics director Margaret M. FitzPatrick received a grant of stock options for 20,400 shares of AN2 Therapeutics, Inc. common stock. The options carry an exercise price of $0.00 per share and are reported as a direct derivative holding.
The option shares are scheduled to vest on February 20, 2027, provided FitzPatrick continues to provide service to the company through that date. After this award, she holds a total of 20,400 stock options according to the filing.
Zakrzewski Joseph S reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Joseph S. Zakrzewski reported receiving a grant of stock options for 20,400 shares on February 20, 2026. These options were awarded at no purchase price on the grant date and represent his total reported derivative holdings of 20,400 options after the transaction.
According to the disclosure, the option shares will vest on February 20, 2027, provided he continues to provide service to the company through that date. This filing reflects an equity-based compensation award rather than an open‑market purchase or sale.
Almitas Capital LLC reported a new significant ownership position in AN2 Therapeutics, Inc. The firm disclosed beneficial ownership of 2,975,164 shares of common stock and warrants, representing about 5.39% of the class. Almitas holds sole voting and dispositive power over all reported securities.
The filing states these securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of AN2 Therapeutics. The position crosses the 5% threshold that requires public disclosure under Schedule 13G rules.